Methodological approaches in application of synthetic lethality screening towards anticancer therapy

D. Canaani*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

25 Scopus citations


A promising direction in the development of selective less toxic cancer drugs is the usage of synthetic lethality concept. The availability of large-scale synthetic low-molecular-weight chemical libraries has allowed HTS for compounds synergistic lethal with defined human cancer aberrations in activated oncogenes or tumour suppressor genes. The search for synthetic lethal chemicals in human/mouse tumour cells is greatly aided by a prior knowledge of relevant signalling and DNA repair pathways, allowing for educated guesses on the preferred potential therapeutic targets. The recent generation of human/rodents genome-wide siRNAs, and shRNA-expressing libraries, should further advance this more focused approach to cancer drug discovery.

Original languageEnglish
Pages (from-to)1213-1218
Number of pages6
JournalBritish Journal of Cancer
Issue number8
StatePublished - 21 Apr 2009


FundersFunder number
German Israeli Foundation
Public Health Service National Cancer Institute


    • Chemical genetic interactions
    • Chemical synthetic lethality
    • Genetic synthetic lethality
    • Oncogenes
    • RNAi
    • Tumour suppressor genes


    Dive into the research topics of 'Methodological approaches in application of synthetic lethality screening towards anticancer therapy'. Together they form a unique fingerprint.

    Cite this